← Back to Search

Proteasome Inhibitor

Pharmacological Study for Multiple Myeloma

Phase 1

Waitlist Available

Led By Kevin Kelly, MD

Research Sponsored by University of Southern California

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

Study Summary

This trial is testing the safety and best dose of a virus that may be able to kill cancer cells, in combination with two drugs that may stop the growth of cancer cells.

Eligible Conditions

Multiple Myeloma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of adverse events assessed by CTCAE version 4.03

Secondary outcome measures

ORR

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (dexamethasone, bortezomib, wild-type reovirus)Experimental Treatment5 Interventions

Patients receive dexamethasone PO, IV, or IM and bortezomib SC (preferably) or IV over 3-5 seconds on days 1, 8, and 15. Patients also receive wild-type reovirus IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Bortezomib

2005

Completed Phase 2

~1140

Dexamethasone

2007

Completed Phase 4

~2590

Wild-type Reovirus

2015

Completed Phase 2

~180

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,139 Total Patients Enrolled

578 Trials studying Multiple Myeloma

188,716 Patients Enrolled for Multiple Myeloma

Oncolytics BiotechIndustry Sponsor

20 Previous Clinical Trials

983 Total Patients Enrolled

2 Trials studying Multiple Myeloma

27 Patients Enrolled for Multiple Myeloma

University of Southern CaliforniaLead Sponsor

905 Previous Clinical Trials

1,596,304 Total Patients Enrolled

3 Trials studying Multiple Myeloma

155 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total enrollment number for participants in this trial?

"The recruitment period for this particular trial has ended. It was initially posted on August 21, 2015 and last edited on August 5th 2022. Fortunately, there are presently 807 trials looking for participants with neoplasms or plasma cell diseases as well as 593 pharmacological studies that are still actively recruiting."

Answered by AI

What ailments can Pharmacological Study typically be employed to address?

"Ophthalmia, sympathetic can often be managed by Pharmacological Study. Additionally, this pharmaceutical intervention may provide relief for those suffering from branch retinal vein occlusion, eye inflammation and macular edema."

Answered by AI

Are patients still being accepted for this research endeavor?

"According to information published on clinicaltrials.gov, this study has ceased recruitment of new patients as of August 5th 2022. While the trial is no longer accepting volunteers, there are 1400 other medical studies actively searching for test subjects at present."

Answered by AI

What other pharmaceutical investigations have been carried out regarding Pharmacological Study?

"Currently, 593 clinical trials researching Pharmacological Study are in operation. Out of these studies, 146 have reached the third and final stage. Mishawaka, Indiana houses the highest concentration of these trials; however, there are 19,884 sites running tests related to this treatment all over the world."

Answered by AI

What kind of risks are posed by Pharmacological Study for patients?

"Due to its Phase 1 classification, our team at Power has assessed the safety of this Pharmacological Study as a 1 on a scale from 1 to 3. This is because there are only limited data available concerning efficacy and safety."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

2015. "Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02514382.